AVDL Annual CFF
$135.34 M
+$120.79 M+830.59%
31 December 2023
Summary:
As of January 23, 2025, AVDL annual cash flow from financing activities is $135.34 million, with the most recent change of +$120.79 million (+830.59%) on December 31, 2023. During the last 3 years, it has fallen by -$44.35 million (-24.68%). AVDL annual CFF is now -24.68% below its all-time high of $179.68 million, reached on December 31, 2020.AVDL Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVDL Quarterly CFF
$1.18 M
+$454.00 K+62.79%
30 September 2024
Summary:
As of January 23, 2025, AVDL quarterly cash flow from financing activities is $1.18 million, with the most recent change of +$454.00 thousand (+62.79%) on September 30, 2024. Over the past year, it has increased by +$22.29 million (+105.58%). AVDL quarterly CFF is now -99.04% below its all-time high of $122.92 million, reached on March 31, 2018.AVDL Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVDL TTM CFF
-$6.02 M
-$29.28 M-125.88%
30 September 2024
Summary:
As of January 23, 2025, AVDL TTM cash flow from financing activities is -$6.02 million, with the most recent change of -$29.28 million (-125.88%) on September 30, 2024. Over the past year, it has dropped by -$141.36 million (-104.45%). AVDL TTM CFF is now -103.35% below its all-time high of $179.68 million, reached on December 31, 2020.AVDL TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
AVDL Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +830.6% | +105.6% | -104.5% |
| 3 y3 years | -24.7% | -98.7% | -104.2% |
| 5 y5 years | +20.1% | -98.7% | -104.2% |
AVDL Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | >+9999.0% | -98.7% | +105.6% | -103.7% | at low |
| 5 y | 5-year | -24.7% | >+9999.0% | -99.0% | +105.6% | -103.3% | at low |
| alltime | all time | -24.7% | +669.8% | -99.0% | +105.6% | -103.3% | +80.4% |
Avadel Pharmaceuticals Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $1.18 M(+62.8%) | -$6.02 M(-125.9%) |
| June 2024 | - | $723.00 K(-94.5%) | $23.26 M(-79.6%) |
| Mar 2024 | - | $13.19 M(-162.5%) | $114.08 M(-15.7%) |
| Dec 2023 | $135.34 M(+830.6%) | -$21.11 M(-169.3%) | $135.34 M(-17.0%) |
| Sept 2023 | - | $30.46 M(-66.7%) | $163.07 M(+13.8%) |
| June 2023 | - | $91.54 M(+165.8%) | $143.32 M(+205.1%) |
| Mar 2023 | - | $34.44 M(+420.1%) | $46.98 M(+223.0%) |
| Dec 2022 | $14.54 M(+5429.7%) | $6.62 M(-38.2%) | $14.54 M(+83.6%) |
| Sept 2022 | - | $10.71 M(-323.1%) | $7.92 M(-395.6%) |
| June 2022 | - | -$4.80 M(-339.1%) | -$2.68 M(-226.2%) |
| Mar 2022 | - | $2.01 M(>+9900.0%) | $2.12 M(+707.2%) |
| Dec 2021 | $263.00 K(-99.9%) | $0.00(-100.0%) | $263.00 K(-41.0%) |
| Sept 2021 | - | $114.00 K(>+9900.0%) | $446.00 K(+41.1%) |
| June 2021 | - | $0.00(-100.0%) | $316.00 K(-99.7%) |
| Mar 2021 | - | $149.00 K(-18.6%) | $117.62 M(-34.5%) |
| Dec 2020 | $179.68 M(<-9900.0%) | $183.00 K(-1243.8%) | $179.68 M(+0.1%) |
| Sept 2020 | - | -$16.00 K(-100.0%) | $179.46 M(+0.0%) |
| June 2020 | - | $117.31 M(+88.6%) | $179.43 M(+189.0%) |
| Mar 2020 | - | $62.21 M(<-9900.0%) | $62.09 M(<-9900.0%) |
| Dec 2019 | -$27.00 K(-100.0%) | -$41.00 K(0.0%) | -$27.00 K(-56.5%) |
| Sept 2019 | - | -$41.00 K(+10.8%) | -$62.00 K(-86.1%) |
| June 2019 | - | -$37.00 K(-140.2%) | -$446.00 K(-95.6%) |
| Mar 2019 | - | $92.00 K(-221.1%) | -$10.16 M(-109.0%) |
| Dec 2018 | $112.66 M(-583.1%) | -$76.00 K(-82.1%) | $112.66 M(+5.6%) |
| Sept 2018 | - | -$425.00 K(-95.6%) | $106.71 M(+3.4%) |
| June 2018 | - | -$9.76 M(-107.9%) | $103.20 M(+3.2%) |
| Mar 2018 | - | $122.92 M(-2139.7%) | $100.00 M(-528.9%) |
| Dec 2017 | -$23.32 M(+193.2%) | -$6.03 M(+53.2%) | -$23.32 M(+35.3%) |
| Sept 2017 | - | -$3.93 M(-69.6%) | -$17.23 M(+23.8%) |
| June 2017 | - | -$12.95 M(+3090.1%) | -$13.92 M(+908.3%) |
| Mar 2017 | - | -$406.00 K(-800.0%) | -$1.38 M(-82.6%) |
| Dec 2016 | -$7.95 M(-66.5%) | $58.00 K(-109.3%) | -$7.95 M(-48.7%) |
| Sept 2016 | - | -$624.00 K(+52.6%) | -$15.51 M(-23.5%) |
| June 2016 | - | -$409.00 K(-94.1%) | -$20.27 M(-33.9%) |
| Mar 2016 | - | -$6.98 M(-7.0%) | -$30.65 M(+29.1%) |
| Dec 2015 | -$23.75 M(-124.7%) | -$7.50 M(+39.5%) | -$23.75 M(+614.7%) |
| Sept 2015 | - | -$5.38 M(-50.2%) | -$3.32 M(-179.0%) |
| June 2015 | - | -$10.79 M(>+9900.0%) | $4.20 M(-73.5%) |
| Mar 2015 | - | -$79.00 K(-100.6%) | $15.84 M(-83.5%) |
| Dec 2014 | $96.00 M(+425.3%) | $12.93 M(+501.5%) | $96.00 M(+10.4%) |
| Sept 2014 | - | $2.15 M(+154.3%) | $86.96 M(+2.8%) |
| June 2014 | - | $845.00 K(-98.9%) | $84.62 M(+0.7%) |
| Mar 2014 | - | $80.07 M(+1959.5%) | $84.03 M(+359.8%) |
| Dec 2013 | $18.27 M(+162.7%) | $3.89 M(-2224.6%) | $18.27 M(+28.3%) |
| Sept 2013 | - | -$183.00 K(-174.1%) | $14.24 M(-5.8%) |
| June 2013 | - | $247.00 K(-98.3%) | $15.12 M(-26.4%) |
| Mar 2013 | - | $14.32 M(<-9900.0%) | $20.54 M(+195.3%) |
| Dec 2012 | $6.96 M | -$141.00 K(-120.5%) | $6.96 M(-3.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2012 | - | $687.00 K(-87.9%) | $7.24 M(+2.3%) |
| June 2012 | - | $5.67 M(+664.9%) | $7.08 M(-18.9%) |
| Mar 2012 | - | $741.00 K(+429.3%) | $8.72 M(+42.0%) |
| Dec 2011 | $6.14 M(-893.9%) | $140.00 K(-73.4%) | $6.14 M(-0.7%) |
| Sept 2011 | - | $526.00 K(-92.8%) | $6.19 M(+5.3%) |
| June 2011 | - | $7.32 M(-498.1%) | $5.88 M(-912.0%) |
| Mar 2011 | - | -$1.84 M(-1098.9%) | -$724.00 K(-6.5%) |
| Dec 2010 | -$774.00 K(-51.1%) | $184.00 K(-14.8%) | -$774.00 K(-209.8%) |
| Sept 2010 | - | $216.00 K(-69.7%) | $705.00 K(-44.2%) |
| June 2010 | - | $714.00 K(-137.8%) | $1.26 M(+120.8%) |
| Mar 2010 | - | -$1.89 M(-213.5%) | $572.00 K(-136.1%) |
| Dec 2009 | -$1.58 M(-117.8%) | $1.66 M(+114.9%) | -$1.58 M(-130.6%) |
| Sept 2009 | - | $774.00 K(+3265.2%) | $5.18 M(+10.6%) |
| June 2009 | - | $23.00 K(-100.6%) | $4.69 M(-4.5%) |
| Mar 2009 | - | -$4.04 M(-148.0%) | $4.91 M(-44.7%) |
| Dec 2008 | $8.88 M(+193.8%) | $8.43 M(+2921.9%) | $8.88 M(+2388.0%) |
| Sept 2008 | - | $279.00 K(+14.8%) | $357.00 K(>+9900.0%) |
| June 2008 | - | $243.00 K(-442.3%) | $2000.00(-99.9%) |
| Mar 2008 | - | -$71.00 K(-24.5%) | $2.93 M(-3.2%) |
| Dec 2007 | $3.02 M(-44.8%) | -$94.00 K(+23.7%) | $3.02 M(+13.4%) |
| Sept 2007 | - | -$76.00 K(-102.4%) | $2.67 M(-66.7%) |
| June 2007 | - | $3.17 M(>+9900.0%) | $8.00 M(+44.3%) |
| Mar 2007 | - | $26.00 K(-105.8%) | $5.55 M(+1.2%) |
| Dec 2006 | $5.48 M(-74.0%) | -$451.00 K(-108.6%) | $5.48 M(-62.2%) |
| Sept 2006 | - | $5.26 M(+639.8%) | $14.52 M(+187.1%) |
| June 2006 | - | $711.00 K(-1923.1%) | $5.06 M(-42.2%) |
| Mar 2006 | - | -$39.00 K(-100.5%) | $8.74 M(-58.5%) |
| Dec 2005 | $21.08 M(+314.5%) | $8.59 M(-304.4%) | $21.08 M(+27.4%) |
| Sept 2005 | - | -$4.20 M(-195.6%) | $16.55 M(-22.4%) |
| June 2005 | - | $4.40 M(-64.3%) | $21.32 M(+24.6%) |
| Mar 2005 | - | $12.30 M(+203.5%) | $17.11 M(+236.4%) |
| Dec 2004 | $5.09 M(-93.2%) | $4.05 M(+609.6%) | $5.09 M(-93.2%) |
| Sept 2004 | - | $571.00 K(+208.6%) | $74.76 M(+0.8%) |
| June 2004 | - | $185.00 K(-33.5%) | $74.19 M(-0.6%) |
| Mar 2004 | - | $278.00 K(-99.6%) | $74.63 M(+0.3%) |
| Dec 2003 | $74.43 M(>+9900.0%) | $73.73 M(>+9900.0%) | $74.43 M(>+9900.0%) |
| Sept 2003 | - | $0.00(-100.0%) | $703.00 K(0.0%) |
| June 2003 | - | $628.00 K(+737.3%) | $703.00 K(+837.3%) |
| Mar 2003 | - | $75.00 K(-175.0%) | $75.00 K(-175.0%) |
| Dec 2002 | $402.00 K(-305.1%) | - | - |
| Dec 2001 | -$196.00 K(-101.7%) | - | - |
| Dec 2000 | $11.62 M(<-9900.0%) | - | - |
| Dec 1999 | -$40.00 K(-100.4%) | - | - |
| Dec 1998 | $9.85 M(+1540.8%) | - | - |
| Mar 1998 | - | -$100.00 K(<-9900.0%) | -$100.00 K(<-9900.0%) |
| Dec 1997 | $600.00 K(-97.8%) | - | - |
| Dec 1996 | $27.90 M | - | - |
| Mar 1996 | - | $0.00 | $0.00 |
FAQ
- What is Avadel Pharmaceuticals annual cash flow from financing activities?
- What is the all time high annual CFF for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals annual CFF year-on-year change?
- What is Avadel Pharmaceuticals quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals quarterly CFF year-on-year change?
- What is Avadel Pharmaceuticals TTM cash flow from financing activities?
- What is the all time high TTM CFF for Avadel Pharmaceuticals?
- What is Avadel Pharmaceuticals TTM CFF year-on-year change?
What is Avadel Pharmaceuticals annual cash flow from financing activities?
The current annual CFF of AVDL is $135.34 M
What is the all time high annual CFF for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high annual cash flow from financing activities is $179.68 M
What is Avadel Pharmaceuticals annual CFF year-on-year change?
Over the past year, AVDL annual cash flow from financing activities has changed by +$120.79 M (+830.59%)
What is Avadel Pharmaceuticals quarterly cash flow from financing activities?
The current quarterly CFF of AVDL is $1.18 M
What is the all time high quarterly CFF for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high quarterly cash flow from financing activities is $122.92 M
What is Avadel Pharmaceuticals quarterly CFF year-on-year change?
Over the past year, AVDL quarterly cash flow from financing activities has changed by +$22.29 M (+105.58%)
What is Avadel Pharmaceuticals TTM cash flow from financing activities?
The current TTM CFF of AVDL is -$6.02 M
What is the all time high TTM CFF for Avadel Pharmaceuticals?
Avadel Pharmaceuticals all-time high TTM cash flow from financing activities is $179.68 M
What is Avadel Pharmaceuticals TTM CFF year-on-year change?
Over the past year, AVDL TTM cash flow from financing activities has changed by -$141.36 M (-104.45%)